Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of the business’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $22.05, for a total value of $165,375.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Shares of DNLI opened at $20.81 on Tuesday. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of -53.36 and a beta of 2.03. Denali Therapeutics Inc has a 12 month low of $12.32 and a 12 month high of $28.86. The company has a debt-to-equity ratio of 0.14, a quick ratio of 14.67 and a current ratio of 11.55.
Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Wednesday, May 8th. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.01). The company had revenue of $4.21 million for the quarter, compared to analyst estimates of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. On average, equities research analysts forecast that Denali Therapeutics Inc will post -1.49 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in Denali Therapeutics by 207.3% in the third quarter. JPMorgan Chase & Co. now owns 10,554 shares of the company’s stock valued at $229,000 after buying an additional 7,120 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Denali Therapeutics by 232.9% in the third quarter. Bank of New York Mellon Corp now owns 203,696 shares of the company’s stock valued at $4,428,000 after buying an additional 142,500 shares during the last quarter. Credit Suisse AG lifted its stake in Denali Therapeutics by 117.0% in the third quarter. Credit Suisse AG now owns 25,894 shares of the company’s stock valued at $564,000 after buying an additional 13,960 shares during the last quarter. Jane Street Group LLC bought a new stake in Denali Therapeutics in the third quarter valued at $218,000. Finally, Man Group plc bought a new stake in Denali Therapeutics in the third quarter valued at $228,000. 71.33% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Insider Selling: Denali Therapeutics Inc (DNLI) COO Sells 7,500 Shares of Stock” was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://dakotafinancialnews.com/2019/05/14/insider-selling-denali-therapeutics-inc-dnli-coo-sells-7500-shares-of-stock.html.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Read More: What are the benefits of a balanced fund?
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.